Calcimimetic agents for the treatment of hyperparathyroidism

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 5, 2001, Pages 575-580

  Goodman, William G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; CALCIUM SENSING RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; R 568; VITAMIN D RECEPTOR;

CALCIUM HOMEOSTASIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HEMODIALYSIS; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM; PARATHYROID HORMONE; RECEPTORS, CALCIUM-SENSING; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034877376     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200109000-00005     Document Type: Review

References (44)

1. Extracellular calcium sensing and extracellular calcium signaling
2. Calcium receptors as novel drug targets
3. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs
4. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid
5. N-linked glycosylation of the human Ca2+ receptor is essential for its expression at the cell surface
6. Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction
7. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells
8. Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function
9. Dimerization of the calcium-sensing receptor occurs within the extracellular domain and is eliminated by Cys → Ser mutations at Cys101 and Cys236
10. Domains determining ligand specificity for Ca2+ receptors
11. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain
12. Protein kinase C phosphorylation of threonine at position 888 in Ca2+o-sensing receptor (CaR) inhibits coupling to Ca2+ store release
13. The carboxyl terminus of the human calcium receptor. Requirements for cell-surface expression and signal transduction
14. A carboxyl-terminal domain controls the cooperativity for extracellular Ca2+ activation of the human calcium sensing receptor. A study with receptor-green fluorescent protein fusions
15. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue
16. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure
17. Recent developments in the management of secondary hyperparathyroidism
18. Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat
19. RNA-protein binding and posttranscriptional regulation of parathyroid hormone gene expression by calcium and phosphate
20. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations
21. Association between total serum calcium and the A986S polymorphism of the calcium-sensing receptor gene
22. Calcimimetics with potent and selective activity on the parathyroid calcium receptor
23. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
24. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium
25. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low- turnover bone and osteomalacia
26. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone
27. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats
28. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
29. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
30. Differential effects of menopause and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT)
31. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor
32. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
33. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism
34. Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia
35. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice
36. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism
37. NPS R-568 halts or reverses osteitis fibrosa in uremic rats
38. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
39. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent
40. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication
41. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
42. Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2
43. Expression of extracellar calcium-sensing receptor in human osteoblastic MG-63 cell line
44. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism